Cyclerion Therapeutics, Inc.
CYCN
$3.00
-$0.01-0.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 17.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 17.14% | |||
| Cost of Revenue | 40.66% | 49.14% | |||
| Gross Profit | -244.27% | -3.98% | |||
| SG&A Expenses | 84.45% | -12.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.25% | -0.96% | |||
| Operating Income | -282.94% | 16.70% | |||
| Income Before Tax | -297.62% | 18.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -297.62% | 18.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -297.62% | 18.14% | |||
| EBIT | -282.94% | 16.70% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -260.28% | 30.70% | |||
| Normalized Basic EPS | -260.46% | 30.72% | |||
| EPS Diluted | -622.70% | 30.70% | |||
| Normalized Diluted EPS | -260.46% | 30.72% | |||
| Average Basic Shares Outstanding | 10.34% | 18.17% | |||
| Average Diluted Shares Outstanding | 10.34% | 18.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||